Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection is a research paper published in Cancer Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 38 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Center for Clinical and Translational Science, Ohio State University
Grant: P30 CA016058
Center for Strategic Scientific Initiatives, National Cancer Institute
Grant: R01 CA198128
National Institutes of Health
Grant: 3P30CA016058-15S1
CORE--HORMONE RECEPTOR LABORATORY
National Institutes of Health
Grant: 3R01CA198128-06S1
Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer
FWCI
2.13
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals